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Abstract
Breast cancer is a malignant tumor that starts in the cells of the breast. A malignant tumor is a group of cancer cells that can grow into near
tissues or invading the distant areas of the body. The disease occurs almost entirely in women, but men can get it, too. Survival rate, recurrence
detection and disease-free survival rate (DFS) are the main patient's outcome and prognosis measures. Breast cancer outcomes are vary among
different stages of the disease. There are five stages of breast cancer named as 0, 1, 2, 3, and 4. Prognosis helps doctors to save patients' lives by
estimating how patient will progress in the therapy plan by comparing the patient's results with another patient's has the same disease characteristics and completed his therapy plan. In Egypt breast cancer represented 21.6% of 33,000 women cancer deaths Ibrahim et al.,2014, with
incidence rate (48.8/100,000) and mortality rate (19.2/100,000). We selected a sample about 1692 cases were diagnosed as breast cancer patients
at the period from 2010 to 2012 taken from the cases recorded in the Tumors Hospital and Institute of First Settlement one of the National
Cancer Institute “NCI” cancer hospitals in Egypt. NCI is the central cancer institute in Egypt. We select the main sufficient attributes to building
a prognosis predictive model 0.1471 records have been selected form the whole sample. The data set we select is used to compute and predict the
three main outcome of prognosis measure at two level, data level for the complete data set, stage level for every stage of breast cancer separately.
The study uses efficient five prediction models with highest accuracy. Results shows that the 5-years survival rate and local recurrence was in
continuous decreasing since 2010 to 2012. Metastatic as a type of breast cancer recurrence was 20.74% in 2010, 17.59% in 2011 and 22.35% in
2012.The DFS (Disease-Free Survival) have the worst rate ever in 2012 as 7.13% after it was 30.37% in 2010.Prognosis predictive models results
shows that the SVM classifiers is the most accurate model to predict the three prognosis measures at the two data level.
Copyright © 2018 Faculty of Computers and Information Technology, Future University in Egypt. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Breast cancer is considered as the highest cancer type in
women [1,2]. It is one of the most dangerous, deadly diseases
at the present times, which infects women and men. The
highly percentage of cases are happening to women. Early
diagnosis is making the disease outcome very good, especially
at the first phase.
* Corresponding author.
E-mail addresses: aattia.elshazly@gmail.com (A.A. Said), drlaila_mohamed@
yahoo.com (L.A. Abd-Elmegid), sherifkholeif@yahoo.com (S. Kholeif),
gaberayman@hotmail.com (A.A. Gaber).
Peer review under responsibility of Faculty of Computers and Information
Technology, Future University in Egypt.

Breast Cancer Staging: Stage is typically communicated
as a number on a size of 0 through 4 with organize
0 depicting non-invasive diseases that stay inside their
unique area and stage 4 portraying intrusive tumors that have
spread outside the bosom to different parts of the body [3].
Table 1 shows the TNM staging system is using for staging
the breast cancer based on 3 values, these values represents
Tumor size (TX, T0, T1, T2, T3, and T4), number of the
involved Lymph Node (NX, N0, N1, N2 and N3) and
Metastasis status (MX, M0 and M1) if the cancer has spread
to other parts of the body beyond the breast.
Survival rate (SR), Disease-Free Survival (DFS) and the
Detection of Recurrence: are types of the breast cancer
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prognosis outcome measures. Survival rates tell what portion
of people with the same type and stage of cancer are still alive
a certain amount of time usually 5 years (5-years survival rate)
after they were diagnosed. They can't tell how long they will
live, but they help give a better understanding about how likely
it is that they treatment will be successful. Disease Free Survival (DFS) in breast cancer, the length of time after primary
treatment for a cancer ends that the patient survives without
any signs or symptoms of that cancer. In a clinical trial,
measuring the disease-free survival is one way to see how well
a new treatment works. Also called DFS, relapse-free survival,
and RFS.
In Egypt breast cancer represented 21.6% of 33,000 women
cancer deaths according WHO cancer country profiles 2014,
with incidence rate (48.8/100,000) and mortality rate (19.2/
100,000) [1]. Black African countries have the poorest prognosis and lowest incidence rates. The highest incidence rate
was found in Belgium 147.5/10,000 [5].United Kingdom has
the highest 5-years survival rate with 87% in 2010 [6] and
South Korea with 90% in 2012 [7].
Data mining is the process of pattern discovery and
extraction where huge amount of data is involved. Data mining
and healthcare field have implemented some detection systems
and other various healthcare related systems from the clinical,
diagnosis and prognosis data. In this paper we using classifying
techniques to predict the breast cancer prognosis. We selected
five classifiers: Support Vector Machine (SVM), Random Trees
(RT), Linear Support Vector Machine (LSVM), Bayes Network
(BN) and Logistic Regression (LR) to do this task.
2. Related work
Rohit J.Kate et al. [8] they built models to predicting breast
cancer stages survivability using three classifiers: naïve bayes,
logistic regression and decision trees with the SEER data set.
They found that predicting the survivability for every stage
separately achieving high accuracy than predicting the survivability to the dataset as one unit.
Houriyeh Ehtemam et al. [9] they introduced a comparison
between 64 data mining models to prognoses and early diagnosis breast cancer and apply these models on 208 record with
10 attributes were between 2014 and 2015 in Iran. They found
that bayes net was the highest accuracy model with 95.7%.

Fig. 1. Full dataset outcome by years.
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Table 1
TNM staging system [4].
Stage No.

Stage Subtype

TNM Values

0
1
2
3

e
e
2A
2B
3A

4

3B
3C
e

Tis,N0,M0
T1,N0,M0
T0,N1,M0 Or T1,N1,M0 Or T2,N0,M0
T2,N1,M0 Or T3,N0,M0
T0,N2,M0 Or T1,N2,M0 Or T2,N2,M0
Or T3,N1,M0 Or T3,N2,M0
T4,N0,M0 OR T4,N1,M0 Or T4,N2,M0
Any T,N3,M0
AnyT,Any N,M1

Table 2
Selceted attributes.
#

Attributes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Year of Diagnosis
Date of Birth
Death/Last Follow Year
T (TNM)
N (TNM)
M (TNM)
Tumor Size (Category)
Tumor Size (Cm)
Stage
Stage Subtype
Histological Type
Histological Grade
LN Status
No. of Positive Nodes
ER Status
PR Status
HER-2 Status
HER-2 Score
Surgery
Surgery Location
Surgery Year
Therapy 1
Therapy 2
Therapy 3
Recurrence Type
Recurrence Year
Metastatic Location
Status
Disease Free Survival
Disease Free Survival e Year

Table 3
Breast cancer main outcomes by stages.
Stage

All Stages

1

2

3

4

# of Records
% of Survived
% of Local Recurrence
% of Metastatic
% of DFS

1471
82.73
3.54
20.46
14.55

122
89.34
0.82
12.30
24.59

741
87.18
3.24
14.98
17.27

597
76.55
4.52
27.97
9.38

11
45.45
0.00
72.73
0.00

M. Mehdi Owrang O [10]. using naïve bayes and association rules on SEER dataset with 16 attributes to predicting
breast cancer survivability by lymph node, no. of positive
lymph nodes, stage, histological grade and race.
Hadi Lotfnezhad Afsharet.al [11] using three classifiers to
build a breast cancer survival prediction model on the SEER
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Fig. 2. 5-years survival rate by stages.

Fig. 3. Recurrence detection by stages.
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dataset. SVM model was achieved the highest accuracy with
97.7%, CHAID 82.2% and Bayes Net 81.8%.
Woojae Kim et al. [12] they built a model using SVM
technique to predict the recurrence of the breast cancer.733
records were selected to this study. They compared between a
SVM and ANN of data mining to develop a recurrence
prognosis model. SVM scored 84.58% accuracy.
Hamid Karim Khani Zand [13] he made a comparison
between many classifiers to predict survivability of breast
cancer. He use the SEER dataset.C4.5 classifiers was more
accurate than the other two classifiers with 86.7% accuracy.
Mamour Gueye et al. [14] specifying outcomes of patients
with inflammatory breast cancer (IBC) treated in a hospital in
Dakar. They found that the mean time to recurrence was 11.2
months. This recurrence was observed in 45.5% of cases. The
median overall survival was 13.3 months (CI 95%
8.576e18.526), the survival rate was 31.8%.
Lone Winther Lietzen et al. [15] studying the OS rate based
on the age ranges. The overall 1-year survival improved
steadily over the period from 90.9% in 1998e2000 to 94.4%
in 2007e2009.5-year survival to improve from 70.0% in
1998e2000 to 74.7% in 2007e2009.
Omar Farouk et al. [16] studying the breast cancer characteristics, biological behavior and outcome in the Egyptian
women  35.Based on the results they found that the breast
cancer in the young Egyptian women has more aggressive
biologic behavior at advanced stages so the treatment strategies have to be tailored in a very precise manner. The median
DFS was 61 months, the 3-year and 5-year disease-free survival were 58% and 50%, respectively. The 3-year and 5-year
OS were 88% and 68%, respectively.
S.Kharya [17] she comparing many of classifiers: Decision
Trees, Association rule, Neural Network, NA€IVE BAYES,
SUPPORT VECTOR MACHINES, Logistic Regression, and
Bayesian Networks to predict breast cancer prognosis. SEER
data set was sued. Decision tree was achieved the highest
accuracy with 93.62%.
3. Contribution

Fig. 4. Disease-free survival by stages.

3.1. Materials and methods
3.1.1. Dataset
The National Cancer Institute “NCI” is the oldest cancer
hospital and institute in Egypt. In 2014 the “NCI Tagamoo
Hospital” for tumors was opened in first settlement to be first
branch of the NCI specialized in breast tumors and all breast
cancer cases were moved to it. Our dataset is the first
Table 4
Prognosis prediction for all the dataset.

Fig. 5. Comparison between USA and Egypt by 5-years survival rate.
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Classifier Name

5-years S.R

Recurrence Detection

DFS

SVM
RT
BN
LR
LSVM

99.18
93.68
89.06
88.72
88.65

99.59
96.8
96.67
96.26
96.6

98.03
87.15
86.27
86.13
86.27

Future Computing and Informatics Journal, Vol. 3 [2018], Iss. 2, Art. 23
394

A.A. Said et al. / Future Computing and Informatics Journal 3 (2018) 391e397

automation process for these cases files, also it's the first time to
calculating the outcome from these records or using these data
in any data mining models. We have chosen all the important
attributes which use in the prognosis process. About 40 attributes were selected from the records and about 30 attributes
were selected to calculate the outcome measures and build the
predictive models. We selected a sample about 1692 cases were
diagnosed as breast cancer patients at the period from 2010 to
2012 0.1471 records have been selected form the whole sample
after preprocessing the data and excluding the missing data.
Records have been transformed from paper form to be an
electronic records. Table 2 shows the selected attributes.
Cases selection criteria:

has the finest outcome as 89.34% 5-years survival rate and
24.59% disease-free survival rate.
Figs. 2e4. represents the differences between the full
dataset and stages outcomes.
Table 7
Disease-Free Survival (DFS) by stages.
Disease-Free Survival
Classifier

All Stage

1

2

3

4

SVM
RT
LSVM
BN
LR

98.03
87.15
86.27
86.27
86.13

99.17
95
95
92.5
90

96.77
88.69
83.98
83,71
84.25

99.5
96.15
91.12
91.12
91.46

e
100
100
100
e

1. Being a female patient.
2. The case has been diagnosed since 5 years or more.
3. A complete data record or at least has the main and
necessary data.
3.2. Results
3.2.1. Outcome calculations
As shown in Fig. 1 We have notice that the 5-years survival
rate was in continuous decreasing since 2010 to 2012.The 5years survival rate was 92.35% in 2010, 84.19% in 2011 and
75.36% in 2012.Also the local recurrence of the breast cancer
was in continuous decreasing as 4.44% in 2010, 4.23% 2011
and 2.43% in 2012.Metastatic as a type of breast cancer
recurrence was 20.74% in 2010, 17.59% in 2011 and 22.35%
in 2012.The 5-years DFS (Disease-Free Survival) have the
worst rate ever in 2012 as 7.13% after it was 30.37% in
2010.Tables 1 and 2.

Fig. 6. 5-Years survival rate prediction accuracy.

3.2.1.1. Breast cancer outcome by stages. Table 3. presents
the three outcome measures calculated for all the stages (full
dataset) and for every stage separately. We notice that Stage1
Table 5
5-Years Survival rate by stages.
5-Years Survival Rate
Classifier
SVM
RT
LSVM
BN
LR

All Stage

1

2

3

4

99.18
93.68
88.65
89.06
88.72

98.33
98.33
97.5
96.67
97.5

99.33
95.96
91.12
92.19
90.71

99.33
96.98
95.81
97.15
94.97

100
100
100
100
100

Fig. 7. Recurrence detection prediction.

Table 6
Recurrence detection by stages.
Recurrence Detection
Classifier

All Stage

1

2

3

4

SVM
RT
LSVM
BN
LR

99.59
96.9
96.6
96.67
96.26

100
99.17
100
100
100

99.46
98.65
96.9
97.17
96.33

99.33
98.49
95.81
97.15
94.97

100
100
100
100
100

https://digitalcommons.aaru.edu.jo/fcij/vol3/iss2/23

Fig. 8. Disease-free survival prediction accuracy.
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Fig. 9. Part of the 5-years survival rate predication model tree.
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As Fig. 5. Shown and according to the American Cancer
Society in 2012 we make this comparison between the USA 5years survival rate and our results based on the Egyptian patient's data. We notice that the Egyptian patients does not
diagnosed as in “Stage 0” ever.
Also we notice that the Egyptian patients have better
prognosis at both of 3 and 4 stage than the American patients.
Stage 3 have the second incidence rate in the Egyptian patients.
3.2.2. Prognosis prediction model
In this part we predict the breast cancer stage-specific
prognosis by using five classifiers techniques. We selected
the five classifiers: Support Vector Machine (SVM), Random
Trees (RT), Bayesian Network (BN), Logistic Regression
(LR), Linear Support Vector Machine (LSVM), which have
achieved the highest accuracy with our dataset using “IBM
SPSS Modeler” data mining software.
As Table 4, shown that the SVM and RT classifiers have the
highest prediction accuracy in the 5-years survival rate. LSVM
and SVM have the highest accuracy in the recurrence detection. In disease-free survival (DFS) prediction SVM and RT
are the highest classifiers in the prediction accuracy.
3.2.2.1. 5-Years survival rate prediction. According to Table
5, SVM classifier has the highest prediction accuracy at the
5-years survival rate prediction. Stage 4 have the best prognosis prediction accuracy between all the stages.Table 7.
3.2.2.2. Recurrence detection prediction. As Table 6 shown
the recurrence detection prediction accuracy stage 1 become
the secondly after stage 4 as highest prognosis prediction for
all the five classifiers.
3.2.2.3. Disease-free survival prediction. According to our
dataset, stage 4 has one value for disease-free survival as
breast cancer outcome in other words stage 4 has no survivors.
Table 7 shows the disease-free survival by stage. SVM
and logistic regression give no predictive results to DFS at
stage 4 because it has one value as prediction target.
3.2.2.4. The 5-years survival rate prediction model. In this
section we will introduce the random tree prediction model for
the 5-years survival rate as an example for our prediction
models.

Metastatic 1 Location in [ "Bone" "Bone, Brain" "Bone,
Brain, Lung" "Bone, Dural" "Bone, Liver" "Bone, Liver,
Lung" "Bone, Lung" "Bone, Skull" "Brain" "Brain, Liver"
"Breast" "Chest" "Lumbosacral" "Lung" "Metastatic Adenocarcinoma" "Metastatic Duct Carcinoma" "Metastatic Recurrence" "No" ] [ Mode: Alive ].
Metastatic 1 Location in [“Bone, Brain" "Bone, Brain,
Lung" "Bone, Dural" "Bone, Liver, Lung" "Bone, Lung"
"Bone, Skull" "Brain, Liver" "Breast" "Chest" "Lumbosacral"
"Metastatic Adenocarcinoma" "Metastatic Duct Carcinoma"
"Metastatic Recurrence”] [Mode: Alive] ¼> Alive.
Metastatic 1 Location in [“Bone" "Bone, Liver" "Brain"
"Lung" "No”] [Mode: Alive].
HER-2 Score in [“0”] [Mode: Alive] ¼> Alive.
HER-2 Score in [“1þ" "2þ" "3þ”] [Mode: Alive] ¼>
Alive.
# of Positive Nodes in [“12" "17" "20" "22" "28" "5" "6"
"8" "9" "Unknown”] [Mode: Dead].
Metastatic 1 Location in [“Bone" "Bone, Liver" "Bone,
Lung" "Brain" "Chest" "Liver, Lung" "Lung”] [Mode: Alive].
Therapy 2 in [“Chemotherapy" "Hormonetherapy”] [Mode:
Alive] ¼> Alive.
Therapy 2 in [“Non" "Radiotherapy”] [Mode: Dead] ¼>
Dead.
Metastatic 1 Location in [“Bone, Brain, Liver" "Bone,
Chest" "Bone, Liver, Lung" "Liver" "Metastatic Adenocarcinoma" "Metastatic Recurrence" "No”] [Mode: Dead] ¼>
Dead.
Recurrence 1 Type in [“No”] [Mode: Alive].
Surgery Location in [“Left, Right" "No”] [Mode: Alive]
¼> Alive.
Surgery Location in [“Left" "Right”] [Mode: Alive].
Age at Diagnosis  70.500 [Mode: Alive].
PR Status in [“þ" "þþ" "þþþ”] [Mode: Alive].
Stage Subtype in [“1" "3B" "3C”] [Mode: Alive] ¼> Alive.
Stage Subtype in [“2A" "2B" "3A" "4”] [Mode: Alive] ¼>
Alive.
PR Status in [“Negative”] [Mode: Alive] ¼> Alive.
Age at Diagnosis >70.500 [Mode: Alive] ¼> Alive. Figs.
6e8.
4. Tree Graph: Fig. 9 shows a part of the 5-years survival rate
predication model tree.
4. Conclusions

1. The model configuration is: training set: 80% and 20% as
testing set.
2. Model accuracy: 93.68%
3. Model rules:
Recurrence 1 Type in [“Local" "Metastatic”] [Mode:
Alive].
# of Positive Nodes in [“0" "1" "10" "11" "13" "14" "15"
"16" "2" "21" "23" "27" "3" "4" "7”] [Mode: Alive].
Metastatic 1 Location in [“Bone, Brain, Liver, Lung"
"Bone, Breast, Liver" "Liver" "Liver, Lung”] [Mode: Dead]
¼> Dead.

https://digitalcommons.aaru.edu.jo/fcij/vol3/iss2/23

Breast cancer is deadly disease but the prognosis of its
outcome can save lives. We built a predictive model to prognosis the breast cancer outcome according to Egyptian patients. The dataset we introduced in this paper, included all the
main and important attributes for prognosis the breast cancer
outcome. Our prediction model achieved the highest accuracy,
which will helps doctors to choose the ideal therapy plan for
the new breast cancer patients. Survival rate, recurrence
detection and disease-free survival (DFS) are the main patient's outcome and prognosis measures. Breast cancer outcomes are vary among different stages of the disease. Breast
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cancer in Egypt represented 21.6% of 33,000 women cancer
deaths with incidence rate (48.8/100,000) and mortality rate
(19.2/100,000).Our dataset was about 1692 cases were diagnosed as breast cancer patients at the period from 2010 to 2012
taken from the cases recorded in the Tumors Hospital and
Institute of First Settlement one of the National Cancer
Institute “NCI” cancer hospitals in Egypt. NCI is the central
cancer institute in Egypt. 1471 records have been selected
form the whole sample. This data set is used to compute and
predict the outcome and prognosis measure for the complete
data set and for every stage separately by using five prediction
models.
Results shows that the 5-years survival rate was in continuous decreasing since 2010 to 2012.The 5-years Survival rate
was 92.35% in 2010, 84.19% in 2011 and 75.36% in 2012.The
disease-free survival rate median was 2 years.
Prognosis predictive models results shows that the SVM
prognosis stage level model for the 5-years survival rate archived
more accurate results than the full data level at stages 2,3 and 4
as 99.33%, 99.33% and 100%. The Other models archived more
accurate results at the stage level for all the four stages. Stage 4
has the more accurate in the stage level for all the models.
Disease-free survival for stage 4 has one value as a prediction
target, SVM and logistic regression have no results for it.
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